5 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood (CANCER-ID)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,
Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the ass ...
Voir le projet
34
Participants partenaires
TERMINÉ
European Patients' Academy on Therapeutic Innovation (EUPATI)
Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,
"The proposed project ""European Patients' Academy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ awareness and participation in pharmaceutical R&D. This patient-led academy will provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical R&D. It will increase the capacity of well-informed patients to be effective advocat ...
Voir le projet
33
Participants partenaires
TERMINÉ
Incorporating real-life clinical data into drug development (GETREAL)
Date du début: 1 oct. 2013, Date de fin: 31 déc. 2016,
When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and efficacy of the medicine in a clinical trial setting. However, assessing the expected future value of the medicines when used in “real world” clinical practice requires additional information next to traditional (pre-authorisation) clinical trials. Regulatory, HTA ...
Voir le projet
32
Participants partenaires
TERMINÉ
Drug Disease Model Resources (DDMORE)
Date du début: 1 mars 2011, Date de fin: 31 août 2016,
Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capa ...
Voir le projet
28
Participants partenaires
TERMINÉ
The Open Pharmacological Concepts Triple Store (OPEN PHACTS)
Date du début: 1 mars 2011, Date de fin: 29 févr. 2016,
Drug discovery is data-hungry and all major pharmaceutical companies maintain extensive in-house instances of public data alongside internal. Analysis and hypothesis generation for drug-discovery projects requires assembly, overlay and comparison of data from many sources, requiring shared identifiers and common semantics. Expression profiles need to be overlaid with gene or pathway identifiers an ...
Voir le projet